Psoriatic arthritis: Current therapy and future approaches

Rheumatology (United Kingdom)

Volumn 54, Issue 1, 2014, Pages 20-28

  Huynh, DoQuyen ^a   Kavanaugh, Arthur ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apremilast; Disease modifying anti rheumatic drug; IL 17 inhibitor; Methotrexate; Psoriatic arthritis; Review; Rituximab; Treatment; Tumour necrosis factor inhibitors; Ustekinumab

Indexed keywords

ABATACEPT; APREMILAST; CORTICOSTEROID; CYCLOSPORIN A; JANUS KINASE INHIBITOR; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RITUXIMAB; TACROLIMUS; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB;

BIOLOGICAL THERAPY; CLINICAL FEATURE; CONSERVATIVE TREATMENT; DISEASE ACTIVITY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; HUMAN; MONOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSORIASIS AREA AND SEVERITY INDEX; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

EID: 84928739044     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu237     Document Type: Review

References (76)

1. Ceponis A, Kavanaugh A. Use of methotrexate in patients with psoriatic arthritis. Clin Exp Rheumatol 2010;28(Suppl 61):s132-7.
2. Chandran V, Gladmann DD. Update on biomarkers in psoriatic arthritis. Curr Rheumatol Rep 2010;12:288-94.
3. Vander CB, Hoffman IE, Zmierczak H et al. Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis. Ann Rheum Dis 2005;64:1145-9.
4. Taylor W, Gladman D, Helliwell P et al. Classification criteria for psoriatic arthritis; development of new criteria from a large international study. Arthritis Rheum 2006;54: 2665-73.
5. Gossec L, Smolen JS, Gaujoux-Viala C et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012;71:4-12.
6. Ritchlin CT, Kavanaugh A, Gladman DD et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009;68:1387-94.
7. Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum 2008;59:686-91.
8. Palominos PE, Gaujoux-Viala C et al. Clinical outcomes in psoriatic arthritis: a systematic literature review. Arthritis Care Res 2012;64:397-406.
9. Wajed J, Helliwell P, Korendowych E et al. Disease assessment in psoriatic spectrum: a modular approach for use in routine clinical practice. Ann Rheum Dis 2014;73: 318-9.
10. Coates LC, Navarro-Coy N, Brown SR et al. The TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomized controlled trial to compare intensive management versus standard care in early psoriatic arthritis. BMC Musculoskelet Disord 2012;21:101.
11. Coates LC, Moverly A, McParland L et al. Results of a randomized control trial comparing tight control of psoriatic arthritis (TICOPA) with standard of care: tight control improves outcome. ACR meeting, San Diego, 2013. Abstract 814.
12. Colebatch AN, Marks JL, van der Heijde DM, Edwards CJ. Safety of nonsteroidal anti-inflammatory drugs and/or paracetamol in people receiving methotrexate for inflammatory arthritis: a Cochrane systematic review. J Rheumatol Suppl 2012;90:62-73.
13. Sarzi-Puttini P, Santandrea S, Boccassini L, Panni B, Caruso I. The role of NSAIDs in psoriatic arthritis: evidence from a controlled study with nimesulide. Clin Exp Rheumatol 2001;19(Suppl 22):S17-20.
14. Brenner M, Molin S, Ruebsam K et al. Generalized pustular psoriasis induced by systemic glucocorticosteroids: four cases and recommendations for treatment. Br J Dermatol 2009;161:964-6.
15. Eder L, Chandran V, Ueng J et al. Predictors of response to intra-articular steroid injection in psoriatic arthritis. Rheumatology 2010;49:1367-73.
16. Marzo-Ortega H, Green MJ, Keenan AM et al. A randomized controlled trial of early intervention with intra articular corticosteroids followed by sulfasalazine versus conservative treatment in early oligoarthritis. Arthritis Care Res 2007;57:154-60.
17. Clegg DO, Reda DJ, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondyloarthopathies. Arthritis Rheum 1999;25: 1957-61.
18. Gupta AK, Grober JS, Hamilton TA. Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial. J Rheumatol 1995;22:894-8.
19. Rahman P, Gladman DD, Cook RJ, Zhou Y, Young G. The use of sulfasalazine in psoriatic arthritis: a clinic experience. J Rheumatol 1998;25:1957-61.
20. Jaimes-Hernandez J, Melendez-Mercado CI, Mendoza-Fuentes A et al. Efficacy of leflunomide 100mg weekly compared to low dose methotrexate in patients with active rheumatoid arthritis: double blind, randomized clinical trial. Rheumatol Clin 2012;8:243-9.
21. Behrens F, Finkenwirth C, Pavelka K et al. Leflunomide in psoriatic arthritis: results from a large European prospective observational study. Arthritis Care Res 2013;65: 464-70.
22. Sakellariou GT, Sayegh FE, Anastasilakis AD, Kapetanos GA. Leflunomide addition in patients with articular manifestations of psoriatic arthritis resistant to methotrexate. Rheumatol Int 2013;33:2917-20.
23. Curtis JR, Beukelman T, Onofrei A et al. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and or leflunomide. Ann Rheum Dis 2012;69:43-7.
24. Salvarani C, Macchioni P, Olivieri I et al. A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol 2001;28: 2274-82.
25. Fraser AD, van Kuijk AWR, Westhovens R et al. A randomized double blind, placebo controlled, multicenter trial of combination therapy with methotrexate plus cyclosporine in patients with active psoriatic arthritis. Ann Rheum Dis 2005;64:859-64.
26. Karanikolas GN, Koukli EM, Katsalira A et al. Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: results from a prospective 12-month nonrandomized unblinded clinical trial. J Rheumatol 2011;38:2466-74.
27. Chandran V, Schentag CT, Gladman DD. Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort. J Rheumatol 2008;35:469-71.
28. Scarpa R, Peluso R, Atteno M et al. The effectiveness of a traditional therapeutic approach in early psoriatic arthritis: results of a pilot randomized 6month trial with methotrexate. Clin Rheumatol 2008;27:823-6.
29. Ritchlin CT, Kavanaugh A, Gladman DD et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009;68:1387-94.
30. Kingsley GH, Kowalczyk A, Taylor H et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology 2012;51:1368-77.
31. Ceponis A, Kavanaugh A. Use of methotrexate in patients with psoriatic arthritis. Clin Exp Rheumatol 2010;28(Suppl 61):S132-7.
32. Baranauskaite A, Raffayova H, Kungurov NV et al. Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis 2012;71:541-8.
33. Ceponis A, Kavanaugh A. Treatment of psoriatic arthritis with biological agents. Semin Cutan Med Surg 2010;29: 56-62.
34. Boehncke WH, Prinz J, Gottlieb A. Biologic therapies for psoriasis. A systematic review. J Rheumatol 2006;33: 1147-51.
35. Salvarani C, Pipitone N, Catanoso M et al. Adalimumab in psoriatic arthritis. J Rheumatol 2012;39(Suppl 89):77-81.
36. Spadaro A, Lubrano E, Ferrara NM, Scarpa R. Etanercept in psoriatic arthritis. J Rheumatol 2012;39(Suppl 89):74-6.
37. Cantini F, Niccoli L, Nannini C, Kaloudi O, Cassara E. Infliximab in psoriatic arthritis. J Rheumatol 2012;39(Suppl 89):71-3.
38. Mease PJ, Goffe BS, Metz J et al. Etanercept treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 2000;356:385-90.
39. Mease PJ, Kivitz AJ, Burch FX et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 2006;33:712-21.
40. Antoni C, Kavanaugh A, van der Heijde D et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab multinational psoriatic arthritis controlled trial (IMPACT). J Rheumatol 2008;35:869-76.
41. Mease PJ, Ory P, Sharp JT et al. Adalimumab for longterm treatment of psoriatic arthritis: 2 year data from the adalimumab effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 2009;68:702-9.
42. Mease PJ, Gladman DD, Ritchlin CT et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52: 3279-89.
43. Kavanaugh A, McInnes I, Mease P et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009;60:976-86.
44. Kavanaugh A, van der Heijde D, McInnes I et al. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a randomized, placebo-controlled trial. Arthritis Rheum 2012;64:2504-17.
45. Kavanaugh A, McInnes I, Mease P et al. Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomized placebo-controlled GO-REVEAL study. Ann Rheum Dis 2013;72:1777-85.
46. Mease PJ, Fleischmann R, Deadhar AA et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24 week results of a phase 3 double-blind randomized placebo controlled study (RAPID-PsA). Ann Rheum Dis 2014;73:233-7.
47. Antoni C, Krueger GG, de Vlam K et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005;64:1150-7.
48. Kavanaugh A, Krueger GG, Beutler A et al. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT2 trial. Ann Rheum Dis 2007;66: 498-505.
49. Atteno M, Peluso R, Costa L et al. Comparison of effectiveness and safety of infliximab, etanercept and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs. Clin Rheumatol 2010;29:399-403.
50. Thorlund K, Druyts E, Avina-Zubieta JA, Mills EJ. Antitumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis. Biologics 2012;6:417-27.
51. Fagerli K, Lie E, van der Heijde D et al. Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study. Ann Rheum Dis 2013;72: 1840-4.
52. Glintborg B, Ostergaard M, Krogh NS et al. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO registry. Arthritis Rheum 2013;65: 1213-23.
53. Cantini F, Niccoli L, Cassara E, Kaloudi O, Nannini C. Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: a long term follow up study. Biologics 2012;6: 201-6.
54. - entheseal resident T cells. Nat Med 2012;18:1069-77.
55. McInnes I, Kavanaugh A, Gottlieb A et al. Ustekinumab in patients with active psoriatic arthritis: results of the phase 3, multicenter, double-blind, placebo-controlled PSUMMIT I study. Ann Rheum Dis 2012;71(Suppl): S107-48.
56. McInnes IB, Kavanaugh A, Gottlieb AB et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3 multicentre, double blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013; 382:780-9.
57. Kavanaugh A, Puig L, Gottlieb A et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 2 year results from a phase 3, multicenter, double-blind, placebo-controlled study. ACR meeting, San Diego, 2013. Abstract L10.
58. McInnes I, Ritchlin C, Rahman P. Ustekinumab is effective in inhibiting radiographic progression in patients with active psoriatic arthritis: integrated data analysis of two phase 3, randomized, placebo-controlled studies. ACR meeting, San Diego, 2013. Abstract 1695.
59. Papp KA, Langley RG, Sigurgeirsson MA et al. Efficacy and safety of secukinumab in the treatment of moderateto-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II does-ranging study. Br J Dermatol 2013;168:412-21.
60. Leonardi C, Matheson R, Zachariae C et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque 45. psoriasis. N Engl J Med 2012;366:1190-9.
61. Papp K, Leonardi C, Menter A et al. Brodalumab, an antiinterleukin-17-receptor antibody for psoriasis. N Engl J Med 2012;366:1181-9.
62. McInnes IB, Sieper J, Braun J et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomized, double blind, placebo controlled, phase II proof of concept trial. Ann Rheum Dis 2014;73:349-56.
63. Genovese M, Mease P, Greenwald M et al. Clinical response to brodalumab, an anti-interleukin-17 receptor antibody, in subjects with psoriatic arthritis. ACR meeting, San Diego, 2013. Abstract 817.
64. Schett G, Wollenhautpt J, Papp K et al. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2012;64:3156-67.
65. Kavanaugh A, Mease PJ, Adebajo AO et al. Long term (52 week) results of a phase 3, randomized controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis. Ann Rheum Dis 2013; 72(Suppl 3):163.
66. Wells A, Edwards CJ, Adebajo A et al. Apremilast in the treatment of DMARD naïve psoriatic arthritis patients: results of a phase 3 randomized controlled trial (PALACE 4). ACR meeting, San Diego, 2013. Abstract L4.
67. Westhovens R, Kremer J, Moreland L et al. Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5 year extended phase IIB study. J Rheumatol 2009;36:736-42.
68. Schiff M, Weinblatt ME, Valente R et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis 2014;73: 86-94.
69. Mease P, Genovese MC, Gladstein G et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized double-blind placebo controlled, phase II trial. Arthritis Rheum 2011;63: 939-48.
70. Sieper J, Porter-Brown B, Thompson L, Harari O, Dougados MJ. Tocilizumab (TCZ) is not effective for the treatment of ankylosing spondylitis (AS): results of phase II international, multicenter, randomized, doubleblind, placebo-controlled trial. Ann Rheum Dis 2012; 1(Suppl 3):110.
71. Ogata A, Umegaki N, Katavama I, Kumanogo A, Tanaka T. Psoriatic arthritis in two patients with an inadequate response to treatment with tocilizumab. Joint Bone Spine 2012;79:85-7.
72. Hughes M, Chinoy H. Successful use of tocilizumab in a patient with psoriatic arthritis. Rheumatology 2013;52: 1728-9.
73. Mamolo C, Harness J, Tan H, Menter A. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patientreported outcomes in phase 2b, randomized, doubleblind, placebo-controlled study in patients with moderateto-severe psoriasis. J Eur Acad Dermatol Venereol 2013; 28:192-203.
74. Wendling D, Dougados M, Berenbaum F et al. A nationwide series: data from the AIR registry of the French Society of Rheumatology. J Rheumatol 2012;39:2327-31.
75. Mease P, Kavanaugh A, Genovese M et al. Rituximab in psoriatic arthritis provides modest clinical improvement and reduces expression of inflammatory biomarkers in skin lesions [abstract]. Arthritis Rheum 2010;62(Suppl): S818.
76. Song IH, Heldmann F, Rudwaleit M et al. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four week clinical trial. Arthritis Rheum 2012;62: 1290-7.